Genmab A/S (OTCMKTS:GNMSF – Get Free Report) saw strong trading volume on Monday . 20,026 shares traded hands during trading, an increase of 771% from the previous session’s volume of 2,300 shares.The stock last traded at $316.00 and had previously closed at $320.9925.
Genmab A/S Price Performance
The stock has a 50-day moving average of $308.44 and a 200 day moving average of $260.08. The company has a market capitalization of $20.88 billion, a PE ratio of 13.47 and a beta of 0.88.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported $6.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.86 by $1.60. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1 billion.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Stories
- Five stocks we like better than Genmab A/S
- With Risk Tolerance, One Size Does Not Fit All
- Market Momentum: 3 Stocks Poised for Major Breakouts
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Reasons Casey’s General Stores Will Continue Trending Higher
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Golden Cross Alert: 3 Stocks With Major Upside Potential
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
